EG667543 Inhibitors
The chemical class termed Vmn1r257 Inhibitors consists of compounds that can indirectly attenuate the function of the Vmn1r257 receptor by impeding associated intracellular signaling processes. The inhibitors target various biochemical pathways that are potentially engaged by the receptor, including tyrosine kinase signaling, PLC-mediated second messenger generation, calcium signaling, and PI3K pathways. For example, Genistein and U73122 serve to inhibit tyrosine kinases and PLC, respectively, thereby disrupting the initial signaling events that Vmn1r257 activation may initiate.
Compounds such as W7 and KN-93 target calcium signaling, a pivotal second messenger system, by antagonizing calmodulin and inhibiting CaMKII, respectively. Further downstream, signaling effectors such as PKA and PKC are targeted by KT5720, Go 6983, and Rp-cAMPS, which serve to impede the amplification and diversification of the receptor's signal. Xestospongin C can prevent the intracellular release of calcium, further contributing to the dampening of the signaling cascade. In addition, NSC 23766 and ML-141 interfere with the cytoskeletal dynamics by inhibiting Rac1 and Cdc42 GTPases, which can impact cellular responses to Vmn1r257 activation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
An inhibitor of tyrosine kinases, which can disrupt receptor tyrosine kinase-mediated signaling that Vmn1r257 may utilize. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
A calmodulin antagonist, which can interfere with calcium/calmodulin-dependent processes that Vmn1r257 might engage in. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor, which can block the phosphatidylinositol signaling pathway that Vmn1r257 may use. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
An inhibitor of calcium/calmodulin-dependent protein kinase II (CaMKII), potentially affecting Vmn1r257-related signaling. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
A broad-spectrum PKC inhibitor, which can alter signaling pathways that Vmn1r257 may activate. | ||||||
KT 5720 | 108068-98-0 | sc-3538 sc-3538A sc-3538B | 50 µg 100 µg 500 µg | $138.00 $220.00 $972.00 | 47 | |
A PKA inhibitor, which can disrupt cyclic AMP (cAMP)-dependent signaling that Vmn1r257 might influence. | ||||||
Rp-cAMPS | 151837-09-1 | sc-24010 | 1 mg | $203.00 | 37 | |
A cAMP analog that acts as a PKA inhibitor, potentially disrupting signaling related to Vmn1r257 activation. | ||||||
Xestospongin C | 88903-69-9 | sc-201505 | 50 µg | $510.00 | 14 | |
An IP3 receptor antagonist, which can inhibit calcium release from the endoplasmic reticulum that Vmn1r257 may trigger. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
An inhibitor of Rac1, which can affect actin cytoskeleton remodeling and signaling that Vmn1r257 might be involved in. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
A selective inhibitor of Cdc42, another GTPase involved in actin cytoskeleton dynamics possibly linked to Vmn1r257. | ||||||